EUCTR2013-005451-32-HU进行中（未招募）不适用
Effects of F17464 in acute exacerbation of schizophrenia. - FAST (F17464 in Acute Schizophrenia Trial)
Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)0 个研究点目标入组 142 人开始时间: 2014年5月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Demographic Characteristics and Other Baseline Characteristics
- •1.Male or female, 18-64 years of age inclusive;
- •2.For female patient of child-bearing potential:
- •Must have been using an effective method of contraception (defined as surgical or hormonal birth control, or intra-uterine device only), assessed by the investigator, for at least 2 months before the enrolment in the study (Visit 1), and must accept to go on using it during the whole duration of the study and up to 1 month after the study end visit, in order to avoid pregnancy while being exposed to the study treatment. A pregnancy test will be carried out at enrolment visit (Visit 1), at inclusion visit (Visit 2) and at the End Of Treatment visit of concerned patient;
- •Agreement of her male partner(s) to use a condom during each sexual intercourse during the study period and to continue until 1 month after the study end visit;
- •3.For male patient:
- •Agreement to use an effective contraceptive method himself and his female partner(s) during each sexual intercourse during the study period and to continue until 3 months after the study end visit.
- •Diagnostic Criteria
- •Schizophrenia history: Before Visit 1
- •4.Patient with a current primary diagnosis of schizophrenia undergoing an acute exacerbation with prominent active phase symptoms, as described by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM IV-TR) using the MINI 6.0 (Mini-International Neuropsychiatric Interview) for schizophrenia and psychotic disorders related to DSM IV-TR;
- •5.For a minimum of 1 year and maximum 5 years, well-documented diagnosis with the first hospitalization for acute exacerbation of schizophrenia;
- •6.Since the diagnosis of schizophrenia, the average number of hospitalisations should be no higher than 2 per year (the minimum duration of hospitalization should be more than 4 days);
- •7.During the year before Visit 1, maximum 3 acute psychotic episodes that required hospitalization or change of antipsychotic medication or other therapeutic intervention;
- •8.Adequate clinical response to well-conducted treatment courses during previous acute episodes. A well conducted treatment course is defined as an antipsychotic treatment with the usual doses for at least 4 weeks;
- •Current acute episode:
- •9.Structured Clinical Interview for the Positive And Negative Syndrome Scale (SCI-PANSS) with a PANSS total score = 70 to < 120 (at Visit 1 and 2);
- •10.Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behaviour, conceptual disorganization, suspiciousness/persecution;
- •11.Clinical Global Impression of Severity (CGI-S) score = 4 (moderate or severe).
- •12.Antipsychotic initiated for this acute episode and/ or ongoing chronic antipsychotic treatment, with a maximum of 2 antipsychotics needed to be changed (due to inefficacy or safety reasons) ;
- •13.Hospitalization and/ or treatment for the current psychotic episode for less than 2 weeks prior to Visit 1;
- •14.No significant improvement of PANSS total score between enrolment (Visit 1) and inclusion (Visit 2) corresponding to a score improvement < 20% on positive symptoms subscale;
- •Examination
- •15.Normal physical examination results, vital signs and clinical laboratory test results or other results judged not clinically significant by the investigator;
- •16.Body mass index (BMI) = 18 and = 35kg/m2 inclusive.
- •Ethical/legal considerations
- •17.Patient able to
排除标准
- •Related to the pathology
- •1. Patients in their first acute episode of psychosis;
- •2. Current schizophrenic episode with predominant negative symptoms;
- •3. Patient « known to be refractory » defined as lack of significant improvement (no significant relief of symptoms, and no period of good function) despite adequate courses with at least 3 different antipsychotics medication cycles of an adequate duration (at least 4 weeks) and at adequate dosage during the previous 5 years;
- •4. Schizoaffective disorder, schizophreniform disorder and other psychotic disorders;
- •5. Bipolar I and II disorder;
- •6. Pervasive developmental disorder, mental retardation, delirium, dementia, memory impairment and other cognitive disorders that would compromise a reliable assessment according to the investigator’s opinion;
- •7. Known or suspected borderline or antisocial personality disorder or other DSM IV-TR axis II disorder of sufficient severity to interfere with participation in this study;
- •8. History of tardive dyskinesia or chronic extra-pyramidal symptoms (EPS), serotonin syndrome or neuroleptic malignant syndrome;
- •9. Major depressive disorder which requires a pharmacological treatment;
- •10. At imminent risk of injuring him/herself or others or causing significant damage to property, as judged by the investigator;
- •11. Suicidal risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS):
- •· Any suicidal behavior in the past year,
- •· Suicidal ideation of type 4 or 5 in the past month.
- •Related to treatments
- •12. Structured psychotherapy (e.g. cognitive behavioural therapy) started within 6 weeks before Visit 1;
- •13. Electroconvulsive therapy within 3 months before visit 1;
- •14. Previous lack of response to electroconvulsive therapy;
- •15. Treatment ongoing with a depot neuroleptic (even if less than 1 cycle in duration before visit 1);
- •16. Patient having previous treatment course with clozapine within 4 months prior to Visit 1;
- •17. Requirement of concomitant treatment with any of the prohibited medications, supplements, or herbal products listed in Prohibited concomitant treatments for associated drug -drug interactions”, including any psychotropic drug or any drug with psychotropic activity or with a potentially psychotropic component;
- •18. History of intolerance or hypersensitivity to other drugs of the same chemical class as F17464 or to rescue medications or any history of severe drug allergy or hypersensitivity;
- •Related to medical conditions
- •19. History or presence of any significant or uncontrolled medical finding such as cancer or neurological, cardiac, hepatic, metabolic, renal, haematological, muscular, endocrine, respiratory, gastrointestinal, dermatological, venereal disorders or diseases, or of any other significant medical condition that may impact the safety, the interpretation of the results, that might affect the absorption, distribution, biotransformation or excretion of the investigational product and/or the participation of the patient in the study according to the opinion of the investigator;
- •20. History of seizure disorder, stroke, significant head injury, severe chronic movement disorder or psychiatric symptoms possibly secondary to any other organic medical condition;
- •21. Known human immunodeficiency virus (HIV) or hepatitis B or C infection;
- •22. Liver enzyme tests (AST, ALT) > 2x upper limit of normal or any abnormal level judged as clinically sign
研究者
相似试验
进行中（未招募）
1 期
Effects of F17464 in acute exacerbation of schizophrenia.schizophreniaEUCTR2013-005451-32-ROPierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)142
进行中（未招募）
1 期
Effects of F17464 in acute exacerbation of schizophrenia.schizophreniaEUCTR2013-005451-32-LVPierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)142
已完成
2 期
F17464 in Acute Schizophrenia TrialSchizophreniaNCT02151656Pierre Fabre Medicament158
终止
2 期
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsSchizophrenia, Schizoaffective DisorderNCT03669640Hoffmann-La Roche131
尚未招募
不适用
ipid changes in schizophrenia patients compared to healthy controlsCTRI/2021/08/035496Shivaprakash G